Moderna and Merck join forces to advance mRNA therapeutics in cancer treatment SOPHIA ANTIPOLIS, France – March 03, 2023 │mRNA therapeutics against cancer are an area of strong R&D activity, especially since the efficient use of mRNA vaccines to fight the SARS-CoV-2 pandemic. On the other hand, although the number of clinical trials is increasing,[…]
SOPHIA ANTIPOLIS, France – January 13, 2023 │ OriCiro’s synthetic biology and enzyme technologies will support Moderna’s expanding portfolio of mRNA therapeutics and vaccines. Moderna press release here. Moderna is a major and active company in the field of therapeutic mRNA Active development of mRNA technologies for vaccines and therapies Messenger RNAs are under active[…]
SOPHIA ANTIPOLIS, France, January 4, 2023 │ An alternative synthetic mRNA platform — self-amplifying RNA (saRNA)— for vaccines may allow smaller doses of vaccines to be administered. Well positioned on this technology, Arcturus Therapeutics, a San Diego-based company founded in 2013, has a self-amplifying RNA vaccine pipeline for SARS-CoV-2 (COVID-19) and influenza. In December 2022,[…]
SOPHIA ANTIPOLIS, France – November 29, 2022 │ KnowMade has identified high recent IP activity in the field of self-amplifying RNA vaccines. This activity could be the sign of an upcoming revolution in the RNA vaccine market. Self-amplifying RNA is a next-generation platform for mRNA vaccines Compared with traditional vaccines (live-attenuated, inactivated, recombinant etc.), effective[…]